Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease
- PMID: 33331946
- DOI: 10.1093/rheumatology/keaa860
Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease
Abstract
Objectives: Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.
Methods: Consecutive RA patients were enrolled and categorized as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.
Results: Fifty-two RA patients were classified as D2T and 100 as non-D2T. Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA [odds ratio (OR) 1.97 (95%CI 1.08-3.61)]. Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than in non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: (i) 'non-adherent dissatisfied patients'; (ii) patients with 'pain syndromes and obesity'; (iii) patients closest to the concept of 'true refractory RA'.
Conclusions: This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.
Keywords: burden of disease; contributing factors; difficult-to-treat rheumatoid arthritis; risk factors.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.Clin Exp Rheumatol. 2024 Jul;42(7):1398-1406. doi: 10.55563/clinexprheumatol/nyu9er. Epub 2024 Jan 31. Clin Exp Rheumatol. 2024. PMID: 38372714
-
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender.Arthritis Res Ther. 2025 Jan 3;27(1):2. doi: 10.1186/s13075-024-03432-4. Arthritis Res Ther. 2025. PMID: 39754234 Free PMC article.
-
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.Adv Rheumatol. 2024 Aug 6;64(1):55. doi: 10.1186/s42358-024-00396-6. Adv Rheumatol. 2024. PMID: 39107865
-
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.Curr Rheumatol Rep. 2023 Dec;25(12):285-294. doi: 10.1007/s11926-023-01117-6. Curr Rheumatol Rep. 2023. PMID: 37776482 Review.
-
'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.RMD Open. 2022 Jul;8(2):e002387. doi: 10.1136/rmdopen-2022-002387. RMD Open. 2022. PMID: 35896282 Free PMC article. Review.
Cited by
-
Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients.Curr Res Pharmacol Drug Discov. 2024 Feb 16;6:100178. doi: 10.1016/j.crphar.2024.100178. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 38419949 Free PMC article.
-
Effectiveness and safety of treat-to-target strategy for methotrexate-naïve rheumatoid arthritis patients >75 years of age.Rheumatol Adv Pract. 2024 Feb 9;8(1):rkae019. doi: 10.1093/rap/rkae019. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 38425693 Free PMC article.
-
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9. Signal Transduct Target Ther. 2023. PMID: 36797236 Free PMC article. Review.
-
Prevalence and Predictors of Remission and Sustained Remission in Patients with Rheumatoid Arthritis from the United Arab Emirates: A Two-Year Prospective Study.Open Access Rheumatol. 2023 May 10;15:51-63. doi: 10.2147/OARRR.S408894. eCollection 2023. Open Access Rheumatol. 2023. PMID: 37192954 Free PMC article.
-
Association Between Dietary Niacin Intake and Rheumatoid Arthritis in American Women: A Study Based on National Health and Nutrition Examination Survey Database.Int J Womens Health. 2024 Dec 19;16:2209-2219. doi: 10.2147/IJWH.S482294. eCollection 2024. Int J Womens Health. 2024. PMID: 39717391 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical